{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T16:52:56Z","timestamp":1778777576328,"version":"3.51.4"},"reference-count":36,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2022,4,20]],"date-time":"2022-04-20T00:00:00Z","timestamp":1650412800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Increasing evidence has shown P2Y12 inhibitor monotherapy is a feasible alternative treatment for patients after percutaneous coronary intervention (PCI) with stent implantation in the modern era. However, patients with diabetes mellitus (DM) have a higher risk of ischemic events and more complex coronary artery disease. The purpose of this study is to evaluate the efficacy and safety of this novel approach among patients with DM and those without DM. We conducted a systematic review and meta-analysis of randomized controlled trials that compared P2Y12 inhibitor monotherapy with 12 months of dual antiplatelet therapy (DAPT) in patients who underwent PCI with stent implantation. PubMed, Embase, Cochrane library database, ClinicalTrials.gov, and three other websites were searched for our data from the earliest report to January 2022. The primary efficacy outcome was major adverse cardiovascular and cerebrovascular events (MACCE): a composite of all-cause mortality, myocardial infarction, stent thrombosis, and stroke. The primary safety outcome was major or minor bleeding events. The secondary endpoint was net adverse clinical events (NACE) which are defined as a composite of major bleeding and adverse cardiac and cerebrovascular events. A total of four randomized controlled trials with 29,136 patients were included in our meta-analysis. The quantitative analysis showed a significant reduction in major or minor bleeding events in patients treated with P2Y12 inhibitor monotherapy compared to standard DAPT (OR: 0.68, 95% CI: 0.46\u20130.99, p = 0.04) without increasing the risk of MACCE (OR: 0.96, 95% CI: 0.85\u20131.09, p = 0.50). The number of NACE was significantly lower in the patients treated with P2Y12 inhibitor monotherapy (OR: 0.84, 95% CI: 0.72\u20130.97, p = 0.019). In DM patients, P2Y12 inhibitor monotherapy was associated with a lower risk of MACCE compared to standard DAPT (OR: 0.85, 95% CI: 0.74\u20130.98, p = 0.02). Furthermore, P2Y12 inhibitor monotherapy was accompanied by a favorable reduction in major or minor bleeding events (OR: 0.80, 95% CI: 0.64\u20131.05, p = 0.107). In non-DM patients, P2Y12 inhibitor monotherapy showed a significant reduction in major or minor bleeding events (OR: 0.58, 95% CI: 0.38\u20130.88, p = 0.01), but without increasing the risk of MACCE (OR: 0.99, 95% CI: 0.82\u20131.19, p = 0.89). Based on these findings, P2Y12 inhibitor monotherapy could significantly decrease bleeding events without increasing the risk of stent thrombosis or myocardial infarction in the general population. The benefit of reducing bleeding events was much more significant in non-DM patients than in DM patients. Surprisingly, P2Y12 inhibitor monotherapy could lower the risk of MACCE in DM patients. Our study supports that P2Y12 inhibitor monotherapy is a promising alternative choice of medical treatment for patients with DM undergoing PCI with stent implantation in the modern era.<\/jats:p>","DOI":"10.3390\/ijms23094549","type":"journal-article","created":{"date-parts":[[2022,4,21]],"date-time":"2022-04-21T01:55:51Z","timestamp":1650506151000},"page":"4549","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Comparative Efficacy and Safety of P2Y12 Inhibitor Monotherapy and Dual Antiplatelet Therapy in Patients with and without Diabetes Mellitus Undergoing Percutaneous Coronary Intervention"],"prefix":"10.3390","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1994-6205","authenticated-orcid":false,"given":"Wen-Han","family":"Feng","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung 80145, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong-Chieh","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung 80145, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2232-9037","authenticated-orcid":false,"given":"Yi-Hsiung","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Cardiology, Kaohsiung Medical University Hospital, Kaohsiung 80756, Taiwan"},{"name":"Center for Lipid Biosciences, Kaohsiung Medical University Hospital, Kaohsiung 80756, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hsiao-Ling","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung 80145, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3353-7501","authenticated-orcid":false,"given":"Hsiu-Mei","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung 80145, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0275-5442","authenticated-orcid":false,"given":"Chih-Sheng","family":"Chu","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung 80145, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,4,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.jacc.2016.03.513","article-title":"2016 acc\/aha guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: A report of the american college of cardiology\/american heart association task force on clinical practice guidelines","volume":"68","author":"Levine","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S0140-6736(18)31858-0","article-title":"Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: A multicentre, open-label, randomised superiority trial","volume":"392","author":"Vranckx","year":"2018","journal-title":"Lancet (Lond. Engl.)"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1001\/jama.2019.8146","article-title":"Effect of p2y12 inhibitor monotherapy vs dual antiplatelet therapy on cardiovascular events in patients undergoing percutaneous coronary intervention: The smart-choice randomized clinical trial","volume":"321","author":"Hahn","year":"2019","journal-title":"JAMA"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1056\/NEJMoa1908419","article-title":"Ticagrelor with or without aspirin in high-risk patients after pci","volume":"381","author":"Mehran","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1001\/jama.2020.7580","article-title":"Effect of ticagrelor monotherapy vs ticagrelor with aspirin on major bleeding and cardiovascular events in patients with acute coronary syndrome: The tico randomized clinical trial","volume":"323","author":"Kim","year":"2020","journal-title":"JAMA"},{"key":"ref_6","first-page":"1","article-title":"P2y12 inhibitor monotherapy after percutaneous coronary intervention: Is it safe to abandon aspirin?","volume":"37","author":"Feng","year":"2021","journal-title":"Acta Cardiol. Sin."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Yang, Y., Park, G.M., Han, S., Kim, Y.G., Suh, J., Park, H.W., Won, K.B., Ann, S.H., Kim, S.J., and Kim, D.W. (2018). Impact of diabetes mellitus in patients undergoing contemporary percutaneous coronary intervention: Results from a korean nationwide study. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0208746"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1016\/j.jacc.2014.01.064","article-title":"Impact of coronary lesion complexity on drug-eluting stent outcomes in patients with and without diabetes mellitus: Analysis from 18 pooled randomized trials","volume":"63","author":"Kedhi","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"104","DOI":"10.2174\/1570161117666190405165911","article-title":"The growing epidemic of diabetes mellitus","volume":"18","author":"Lovic","year":"2020","journal-title":"Curr. Vasc. Pharmacol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1016\/j.jacc.2020.03.008","article-title":"Ticagrelor with or without aspirin in high-risk patients with diabetes mellitus undergoing percutaneous coronary intervention","volume":"75","author":"Angiolillo","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.atherosclerosis.2020.01.002","article-title":"Association of diabetes with outcomes in patients undergoing contemporary percutaneous coronary intervention: Pre-specified subgroup analysis from the randomized global leaders study","volume":"295","author":"Chichareon","year":"2020","journal-title":"Atherosclerosis"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1093\/ejcts\/ezx334","article-title":"2017 esc focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with eacts","volume":"53","author":"Valgimigli","year":"2018","journal-title":"Eur. J. Cardio-Thorac. Surg. Off. J. Eur. Assoc. Cardio-Thorac. Surg."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1161\/CIRCULATIONAHA.111.047498","article-title":"Ticagrelor compared with clopidogrel by geographic region in the platelet inhibition and patient outcomes (plato) trial","volume":"124","author":"Mahaffey","year":"2011","journal-title":"Circulation"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1172\/JCI110814","article-title":"Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man","volume":"71","author":"FitzGerald","year":"1983","journal-title":"J. Clin. Investig."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1111\/j.1538-7836.2007.02356.x","article-title":"Inhibition of the platelet p2y12 receptor for adenosine diphosphate potentiates the antiplatelet effect of prostacyclin","volume":"5","author":"Cattaneo","year":"2007","journal-title":"J. Thromb. Haemost. JTH"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/j.1365-2125.2011.03943.x","article-title":"Anti-platelet therapy: Cyclo-oxygenase inhibition and the use of aspirin with particular regard to dual anti-platelet therapy","volume":"72","author":"Warner","year":"2011","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s40261-020-00947-x","article-title":"P2y12 inhibitor monotherapy after a short dual antiplatelet therapy versus standard-term dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: A contemporary meta-analysis","volume":"40","author":"Ho","year":"2020","journal-title":"Clin. Drug Investig."},{"key":"ref_18","first-page":"n1332","article-title":"P2y12 inhibitor monotherapy or dual antiplatelet therapy after coronary revascularisation: Individual patient level meta-analysis of randomised controlled trials","volume":"373","author":"Valgimigli","year":"2021","journal-title":"BMJ (Clin. Res. Ed.)"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1093\/eurheartj\/ehaa739","article-title":"Short dual antiplatelet therapy followed by p2y12 inhibitor monotherapy vs. Prolonged dual antiplatelet therapy after percutaneous coronary intervention with second-generation drug-eluting stents: A systematic review and meta-analysis of randomized clinical trials","volume":"42","author":"Giacoppo","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1161\/CIRCULATIONAHA.109.913376","article-title":"Diabetes and antiplatelet therapy in acute coronary syndrome","volume":"123","author":"Ferreiro","year":"2011","journal-title":"Circulation"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1111\/j.1538-7836.2004.00836.x","article-title":"Platelet activation in type 2 diabetes mellitus","volume":"2","author":"Ferroni","year":"2004","journal-title":"J. Thromb. Haemost. JTH"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/j.jacc.2007.05.049","article-title":"Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease","volume":"50","author":"Angiolillo","year":"2007","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"594","DOI":"10.21037\/cdt.2018.05.09","article-title":"Diabetes and antiplatelet therapy: From bench to bedside","volume":"8","author":"Franchi","year":"2018","journal-title":"Cardiovasc. Diagn. Ther."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Severino, P., D\u2019Amato, A., Prosperi, S., Magnocavallo, M., Mariani, M.V., Netti, L., Birtolo, L.I., De Orchi, P., Chimenti, C., and Maestrini, V. (2021). Potential role of enos genetic variants in ischemic heart disease susceptibility and clinical presentation. J. Cardiovasc. Dev. Dis., 8.","DOI":"10.3390\/jcdd8090116"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Theofilis, P., Sagris, M., Oikonomou, E., Antonopoulos, A.S., Tsioufis, K., and Tousoulis, D. (2022). Factors associated with platelet activation-recent pharmaceutical approaches. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23063301"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1620\/tjem.231.217","article-title":"Reduced expression of prostacyclin synthase and nitric oxide synthase in subcutaneous arteries of type 2 diabetic patients","volume":"231","author":"Mokhtar","year":"2013","journal-title":"Tohoku J. Exp. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s12933-018-0763-3","article-title":"Endothelial dysfunction and platelet hyperactivity in type 2 diabetes mellitus: Molecular insights and therapeutic strategies","volume":"17","author":"Kaur","year":"2018","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1111\/j.1538-7836.2010.04160.x","article-title":"In the presence of strong p2y12 receptor blockade, aspirin provides little additional inhibition of platelet aggregation","volume":"9","author":"Armstrong","year":"2011","journal-title":"J. Thromb. Haemost. JTH"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.jacc.2019.11.056","article-title":"Ticagrelor with or without aspirin after pci: The twilight platelet substudy","volume":"75","author":"Baber","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e016495","DOI":"10.1161\/JAHA.120.016495","article-title":"Pharmacodynamic comparison of ticagrelor monotherapy versus ticagrelor and aspirin in patients after percutaneous coronary intervention: The template (ticagrelor monotherapy and platelet reactivity) randomized controlled trial","volume":"9","author":"Johnson","year":"2020","journal-title":"J. Am. Heart Assoc."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1177\/1074248418786936","article-title":"Does ticagrelor improve endothelial function?","volume":"24","author":"Moulias","year":"2019","journal-title":"J. Cardiovasc. Pharmacol. Ther."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s12933-019-0882-5","article-title":"Ticagrelor improves blood viscosity-dependent microcirculatory flow in patients with lower extremity arterial disease: The hema-kinesis clinical trial","volume":"18","author":"Rosenson","year":"2019","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.2337\/diabetes.54.8.2430","article-title":"Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment","volume":"54","author":"Angiolillo","year":"2005","journal-title":"Diabetes"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.jacc.2014.06.1170","article-title":"Impaired responsiveness to the platelet p2y12 receptor antagonist clopidogrel in patients with type 2 diabetes and coronary artery disease","volume":"64","author":"Angiolillo","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/j.jacc.2010.11.024","article-title":"Clopidogrel-drug interactions","volume":"57","author":"Bates","year":"2011","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Chen, P.W., Feng, W.H., Ho, M.Y., Su, C.H., Huang, S.W., Cheng, C.W., Yeh, H.I., Chen, C.P., Huang, W.C., and Fang, C.C. (2020). P2y12 inhibitor monotherapy with clopidogrel versus ticagrelor in patients with acute coronary syndrome undergoing percutaneous coronary intervention. J. Clin. Med., 9.","DOI":"10.3390\/jcm9061657"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/9\/4549\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:57:38Z","timestamp":1760137058000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/9\/4549"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,20]]},"references-count":36,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2022,5]]}},"alternative-id":["ijms23094549"],"URL":"https:\/\/doi.org\/10.3390\/ijms23094549","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,20]]}}}